About Insulet (NASDAQ:PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000
Debt
Debt-to-Equity Ratio3.57%
Current Ratio6.24%
Quick Ratio5.85%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$463.77 million
Price / Sales10.97
Cash FlowN/A
Price / CashN/A
Book Value$2.72 per share
Price / Book31.87
Profitability
EPS (Most Recent Fiscal Year)($0.46)
Net Income$-26,830,000.00
Net Margins-5.79%
Return on Equity-29.73%
Return on Assets-4.83%
Miscellaneous
Employees857
Outstanding Shares58,690,000
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.04. The medical instruments supplier earned $130.50 million during the quarter, compared to analysts' expectations of $125.16 million. Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The company's quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) EPS. View Insulet's Earnings History.
When is Insulet's next earnings date?
What price target have analysts set for PODD?
20 brokers have issued 12-month target prices for Insulet's shares. Their forecasts range from $44.00 to $105.00. On average, they expect Insulet's share price to reach $76.7778 in the next twelve months. View Analyst Ratings for Insulet.
What are Wall Street analysts saying about Insulet stock?
Here are some recent quotes from research analysts about Insulet stock:
- 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (3/13/2018)
- 2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR) and Glaukos (GKOS).
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
- Ms. Shacey Petrovic, Pres and Chief Operating Officer (Age 44)
- Mr. Michael L. Levitz, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 44)
- Mr. Bradley A. Thomas, Exec. VP of HR & Organizational Devel. (Age 60)
- Mr. Charles Alpuche, Exec. VP of Global Manufacturing and Operations (Age 58)
Has Insulet been receiving favorable news coverage?
Headlines about PODD stock have trended positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insulet earned a news impact score of 0.29 on Accern's scale. They also gave news stories about the medical instruments supplier an impact score of 46.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $86.69.
How big of a company is Insulet?
Insulet has a market capitalization of $5.19 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.
How can I contact Insulet?
Insulet's mailing address is 600 TECHNOLOGY PARK DRIVE SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Insulet (NASDAQ:PODD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Insulet in the last 12 months. Their average twelve-month price target is $76.7778, suggesting that the stock has a possible downside of 11.43%. The high price target for PODD is $105.00 and the low price target for PODD is $44.00. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.70 | 2.67 | 2.71 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $76.7778 | $73.5625 | $62.1429 | $55.4615 |
| Price Target Upside: | 11.43% downside | 2.98% downside | 9.62% downside | 8.97% downside |
Insulet (NASDAQ:PODD) Consensus Price Target History
Insulet (NASDAQ:PODD) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Insulet (NASDAQ:PODD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.60%
Insulet (NASDAQ PODD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Bradley A. Thomas | EVP | Sell | 3,500 | $85.00 | $297,500.00 | |  |
| 3/15/2018 | Charles Alpuche | COO | Sell | 7,090 | $84.65 | $600,168.50 | | |
| 3/14/2018 | Bradley A. Thomas | EVP | Sell | 7,250 | $83.81 | $607,622.50 | | |
| 3/14/2018 | John A. Fallon | Director | Sell | 9,000 | $84.10 | $756,900.00 | | |
| 3/6/2018 | David A. Lemoine | Director | Sell | 641 | $76.81 | $49,235.21 | | |
| 3/6/2018 | Shacey Petrovic | COO | Sell | 1,319 | $76.81 | $101,312.39 | | |
| 11/13/2017 | James C. Mullen | Director | Buy | 2,500 | $67.45 | $168,625.00 | | |
| 9/6/2017 | Charles Alpuche | EVP | Buy | 2,500 | $58.08 | $145,200.00 | | |
| 5/16/2017 | Michael P. Spears | SVP | Buy | 2,500 | $40.59 | $101,475.00 | | |
| 5/11/2017 | Bradley A. Thomas | EVP | Buy | 3,000 | $38.69 | $116,070.00 | | |
| 5/11/2017 | Jessica Hopfield | Director | Buy | 2,580 | $38.68 | $99,794.40 | | |
| 5/1/2017 | David A. Lemoine | Director | Sell | 1,524 | $43.40 | $66,141.60 | | |
| 3/13/2017 | Regina O. Sommer | Director | Sell | 40,000 | $45.00 | $1,800,000.00 | | |
| 3/6/2017 | David A. Lemoine | Director | Sell | 1,282 | $45.15 | $57,882.30 | | |
| 3/2/2017 | Joseph S. Zakrzewski | Director | Sell | 40,000 | $46.86 | $1,874,400.00 | | |
| 12/9/2016 | Charles Alpuche | SVP | Buy | 6,600 | $37.70 | $248,820.00 | | |
| 12/2/2016 | Patrick J. Sullivan | CEO | Buy | 40,000 | $33.89 | $1,355,600.00 | | |
| 12/1/2016 | Bradley A. Thomas | EVP | Buy | 3,100 | $32.45 | $100,595.00 | | |
| 5/25/2016 | Regina O Sommer | Director | Sell | 8,019 | $30.42 | $243,937.98 | 20,330 | |
| 5/18/2016 | Patrick J Sullivan | CEO | Buy | 45,000 | $27.00 | $1,215,000.00 | 202,795 | |
| 5/13/2016 | Bradley A Thomas | EVP | Buy | 2,975 | $26.63 | $79,224.25 | 51,315 | |
| 5/5/2016 | Bradley A Thomas | EVP | Buy | 1,656 | $30.13 | $49,895.28 | 48,340 | |
| 3/10/2016 | Daniel J Levangie | Insider | Sell | 12,299 | $30.89 | $379,916.11 | 25,358 | |
| 3/7/2016 | Daniel J Levangie | Insider | Sell | 7,663 | $31.15 | $238,702.45 | 9,813 | |
| 3/2/2016 | Jessica Hopfield | Director | Buy | 3,230 | $30.91 | $99,839.30 | 8,838 | |
| 6/5/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $29.39 | $293,900.00 | | |
| 5/28/2015 | Patrick J Sullivan | CEO | Buy | 20,000 | $27.91 | $558,200.00 | | |
| 5/15/2015 | Timothy J Scannell | Director | Buy | 3,500 | $27.05 | $94,675.00 | | |
| 5/5/2015 | Bradley A Thomas | EVP | Buy | 1,000 | $27.26 | $27,260.00 | | |
| 5/5/2015 | Patrick Ryan | COO | Buy | 3,669 | $26.99 | $99,026.31 | | |
| 4/2/2015 | R Anthony Diehl | General Counsel | Sell | 3,372 | $30.96 | $104,397.12 | | |
| 3/9/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $31.93 | $319,300.00 | | |
| 3/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | | |
| 2/12/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | | |
| 1/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $46.08 | $184,320.00 | | |
| 11/3/2014 | Charles T Liamos | Director | Sell | 4,000 | $42.95 | $171,800.00 | | |
| 10/1/2014 | Charles T Liamos | Director | Sell | 4,000 | $36.58 | $146,320.00 | | |
| 10/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $36.59 | $45,737.50 | | |
| 9/10/2014 | Charles T Liamos | Director | Sell | 4,000 | $35.17 | $140,680.00 | | |
| 9/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.30 | $726,000.00 | | |
| 8/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $34.23 | $684,600.00 | | |
| 7/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $40.52 | $810,400.00 | | |
| 7/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $39.65 | $49,562.50 | | |
| 6/11/2014 | R Anthony Diehl | General Counsel | Sell | 17,871 | $37.09 | $662,835.39 | | |
| 6/9/2014 | Peter Devlin | Insider | Sell | 12,314 | $37.10 | $456,849.40 | | |
| 4/8/2014 | Peter Devlin | Insider | Sell | 30,000 | $41.25 | $1,237,500.00 | 79,668 | |
| 4/3/2014 | R Anthony Diehl | General Counsel | Sell | 4,617 | $48.67 | $224,709.39 | 53,246 | |
| 3/6/2014 | R Anthony Diehl | General Counsel | Sell | 12,458 | $49.28 | $613,930.24 | 58,246 | |
| 3/6/2014 | Tracey Haas Wielinski | VP | Sell | 8,275 | $49.21 | $407,212.75 | 24,000 | |
| 2/3/2014 | Charles Liamos | Director | Sell | 11,037 | $42.93 | $473,818.41 | 77,316 | |
| 2/3/2014 | Duane Desisto | CEO | Sell | 20,000 | $42.95 | $859,000.00 | 184,293 | |
| 2/3/2014 | Peter Devlin | Insider | Sell | 30,000 | $42.82 | $1,284,600.00 | 63,081 | |
| 1/3/2014 | Charles Liamos | COO | Sell | 86,000 | $36.02 | $3,097,720.00 | 77,316 | |
| 1/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.07 | $721,400.00 | 184,293 | |
| 12/3/2013 | Charles Liamos | COO | Sell | 63,808 | $36.26 | $2,313,678.08 | 118,194 | |
| 11/18/2013 | Charles Liamos | COO | Sell | 80,000 | $35.60 | $2,848,000.00 | 118,194 | |
| 9/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $33.38 | $667,600.00 | 182,433 | |
| 8/29/2013 | Sally Crawford | Director | Sell | 9,000 | $33.42 | $300,780.00 | 7,000 | |
| 8/15/2013 | Regina Sommer | Director | Sell | 5,000 | $33.32 | $166,600.00 | 16,500 | |
| 8/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.85 | $637,000.00 | | |
| 7/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.51 | $630,200.00 | | |
| 7/1/2013 | Peter Devlin | Insider | Sell | 30,000 | $31.48 | $944,400.00 | | |
| 6/14/2013 | Sally Crawford | Director | Sell | 31,000 | $30.47 | $944,570.00 | | |
| 6/10/2013 | R Anthony Diehl | General Counsel | Sell | 38,455 | $30.50 | $1,172,877.50 | | |
| 6/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $29.76 | $595,200.00 | | |
| 12/3/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.92 | $219,200.00 | | |
| 11/1/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.49 | $214,900.00 | | |
| 9/4/2012 | Brian K Roberts | CFO | Sell | 10,000 | $20.78 | $207,800.00 | | |
| 9/4/2012 | Duane Desisto | CEO | Sell | 20,000 | $20.97 | $419,400.00 | | |
| 9/4/2012 | Ruthann Depietro | VP | Sell | 1,000 | $20.90 | $20,900.00 | | |
(Data available from 1/1/2013 forward)
Insulet (NASDAQ PODD) News Headlines
| Source: |
|
Insulet (NASDAQ:PODD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement
Insulet (NASDAQ PODD) Stock Chart for Saturday, April, 21, 2018
Loading chart…
